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Anaemia increases the risk of maternal and foetal mortality and 
morbidity in pregnancy.(1) Anaemia is functionally defined as an insufficient 
Red Blood Cells (RBC) mass to adequately deliver oxygen to peripheral 
tissues. Haemoglobin (Hb) concentration of 14g/dl and 12g/dl were considered 
as the lower limits of normal, at sea level in adult men and women, 
respectively.(2)  
According to the proposal by World Health Organisation (WHO) expert 
group “anaemia or iron deficiency should be considered to exist” when  
haemoglobin is below the following levels.(1) The cut off points for the 
diagnosis of anaemia is shown in Table 1. 
TABLE - 1 : CUT – OFF POINTS FOR THE DIAGNOSIS OF 
ANAEMIA(1) 
CATEGORY g/dl MCHC% 
Adult Male 13 34 
Adult Female – Non Pregnant 12 34 
Adult Female –  Pregnant 11 34 
Children, 6 months to 6 years 11 34 
Children 6 to 14 years 12 34 
 
Anaemia in non-pregnant women is defined as haemoglobin 
concentration less than 12 g/dl and less than 10 g/dl during pregnancy or the 
puerperium. Haemoglobin concentration is lower in mid pregnancy. Early in 
pregnancy and again near term the haemoglobin level of most healthy women 
with iron stores is 11g/dl or higher. For these reasons the centre for disease 
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control (1990) defined anaemia as less than 11g/dl in the first and third 
trimester and less than 10.5 g/dl in the second trimester.(3) 
Incidence 
Globally 30% of the total world population is anaemic and half of these, 
some 600 million people have iron deficiency.(4) The WHO report gives an 
anaemia prevalence at the global level as 55.9% among the expectant 
mothers.(5)
 
In India 5-6% of general population suffer from the disease. It is 
prevalent among 3% of men and 10 – 14% of women. About 10% of 
attendance in General hospitals is accounted for by anaemia. In specific groups 
like slum dwellers, plantation labourers and pregnant women, the prevalence 
rate is 30-50% or even more.(6) Similarly the incidence at Institute of 
Obstetrices and Gynacology Madras Medical College, Egmore, Chennai was 
also 40% . 
India has probably the highest prevalence of nutritional anaemia in 
women and children. About one half of non-pregnant women and young 
children are estimated to suffer from anaemia. 60-80% of pregnant women are 
anaemic. 20-40% of maternal death is attributed to anaemia. The most frequent 
cause of anaemia is iron deficiency and less frequently folate and Vit B12 
deficiency.(1) 
Incidence of anaemia in pregnancy ranges widely from 40 to 80 % in the 
tropics compared to 10 to 20 % in the developed countries.(7) Survey in 
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different parts of India indicates that about 50 to 60% of women belonging to 
low socioeconomic groups are anaemic in the last trimester of pregnancy. The 
major etiological factors are iron and folic acid deficiency. It is well known that 
anaemia per se is associated with a high incidence of premature birth, 
postpartum haemorrhage  puerperal sepsis and thromboembolic phenomenon in 
the mother.(1) 
Indian Council of Medical Research (ICMR)  in 1989 carried out a 
countrywide evaluation of the anaemia in pregnant women at or beyond 20 
weeks of gestational age.  The prevalence of anaemia was found to be 87%, 
with 32 % of women having Hb less than 8g/dl.(8) Another study by ICMR in 
1992 among pregnant women in second trimester reported a prevalence rate of 
62 %. (9)  The ICMR Multicentric Study under District Nutrition Project 2001, 
showed over all prevalence of anaemia among pregnant women as about 
85%.(10) According to National Family Health Services (NFHS–2) data, the 
prevalence of anaemia among pregnant women was 49.7%.(11) 
Classification of Anaemia 
Major Classification of anaemia: 
1. Marrow production defect (hypoproliferation) 
2. Red cell maturation defect (ineffective erythropoiesis) 
3.  Decreased red cell survival (Blood loss / Haemolysis) 
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Kinetic Classification of Anaemia  
Impaired Erythrocyte Production 
1. Hypoproliferative 
Iron deficiency Anaemia 
• Iron deficiency 
• Anaemia of chronic disorders 
2. Erythropoietin deficiency 
• Renal disease 
• Endocrine deficiencies 
3. Hypoplastic anaemia 
• Aplastic anaemia 
• Pure red cell aplasia 
 4. Infiltration 
• Leukemia 
• Metastatic Carcinoma 
• Myelofibrosis 
 5. Ineffective 
Megaloblastic 
 Vitamin B12 deficiency 
 Folate deficiency 
 Other causes 
Microcyctic 
• Thalassemia 
• Certain sideroblastic anaemia(12) 
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Diagnosis 
There are two steps in the diagnosis of anaemia. 
        1. To establish that the anaemia is due to iron deficiency  
        2. To determine the cause of the iron deficiency. 
The diagnosis of iron deficiency anaemia is often recognised by the 
clinical features, and history. It can be established with certainity only by blood 
examination. Satisfactory response to iron therapy confirms the diagnosis.(13) 
Initial Investigation of Anaemia 
 The initial investigations required for diagnosis of anaemia are  
 
• Full blood count 
• Examination of blood film 
• Serum Ferritin  
• Serum B12 
• Red cell folate 
• Haemolysis screening (if indicated), Reticulocyte count, 
Bilirubin, Lactate dehydrogenase, Haptoglobin 
• Examination of Peripheral Smear     
• Anisocytosis 
• Hypochromic 
• Microcytic(14)  
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Complications of Anaemia 
Severe anaemia in pregnancy is associated with increased maternal 
death. Reports indicate 19% of all  maternal deaths are attributable to 
anaemia.(1) 
 
 
General 
1. High output heart failure 
2. Infections are more common in iron deficiency anaemia (IDA) 
especially those of respiratory, gastro intestinal and urinary tract. 
Tuberculosis is common in them. Cell mediated immunity is 
reduced in these subjects. 
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3. Chronic anaemia reduces the efficiency in work. 
4. Decreased oxygen consumption. 
5. Decreased oxygen affinity due to increased amount of 2,3- 
bisphosphoglycerate and this phosphate compound has the 
capacity to combine with deoxygenated haemoglobin and 
decrease its affinity for oxygen. 
6. Increased tissue perfusion 
7. Increased cardiac output  
8. Increased pulmonary function. 
9. Uncorrected tissue hypoxia. 
During pregnancy 
1. Pre-eclampsia. 
2.  Intercurrent infection- not only does anaemia diminish resistance 
to infection but also pre – existing lesion, if present will flare-up. 
It should be noted that infection itself impairs erythropoiesis by 
bone marrow depression. 
3. Heart failure at 30- 32weeks of pregnancy. 
4. Pre term labour 
During labour  
1. Uterine inertia  
2. Postpartum haemorrhage  
3. Cardiac failure 
4. Shock 
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Puerperium 
1. Puerperal sepsis  
2. Sub involution 
3. Failure of lactation 
4. Puerperal venous thrombosis 
5. Pulmonary embolism 
Effect on Baby 
1. Low birth weight 
2. Perinatal mortality  
3. Intrauterine death – due to severe anoxaemia 
4. Increased perinatal loss.(7) 
To prevent these complications  
 The objectives of the treatment are correction of the deficit in 
haemoglobin mass and eventually restoration of iron stores. Both these 
objectives can be accomplished with orally administrated simple iron 
compounds- ferrous sulphate, fumarate or gluconate – that provide a daily dose 
of about 200mg of elemental iron. If the women cannot or will not take oral 
iron preparations, then parenteral iron is given. To replenish iron stores oral 
therapy should be continued for three months or so after the anaemia has been 
corrected.(3)  
Considerable increase in haemoglobin by an oral agent will obviate the 
need for blood transfusion and parenteral  iron and reduced the maternal 
mortality and morbidity associated with anaemia in pregnancy. 
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Ancient History 
 
The empirical use of iron in the treatment of anaemia dates from ancient 
times. The calcined iron preparation of ancient Hindu medicine, known as 
Lawha Bhasma was prepared by casting sheets of iron and then macerating 
them to a fine white powder in oil, whey , vinegar, cow’s milk.  The Greek 
physicians employed iron for the cure of weakness, a prominent symptoms of 
anaemia, in the attempt to impart to the patient the strength of the iron. Indeed , 
it was believed that, Mars the god of war, had imbued the metal with strength 
and alchemists designated iron as Mars. Patients with marked pallor were given 
drinking water in which old swords, had been allowed to rust, and Celsus 
advised that enlarged spleens be treated by using water in blacksmith shops and 
in which white hot iron had been drenched. He claimed that animals drinking 
such water had abnormally small spleens.(15) 
Recognizing Anaemia In Iron Deficiency Anaemia 
Sydenham was probably the first physician to employ iron in a manner 
that would be approved today; in 1681,  Sydenham prescribed, “steel in 
substance or iron or steel filings steeped in cold rhenish wine”, the dose 
amounting to 0.5 to 1.0g of iron daily.(15) 
The Clinical Picture 
Chlorosis 
Chlorosis (also the ‘green sickness’, morbus virgineus, mal d’amour and 
other names) was described in relatively modern times as ‘a hypochromic 
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anaemia in adolescent girls usually associated with gastrointestinal and 
menstrual disorder.(16) 
Hirsch quotes Sennart stating that ‘pallor or yellow tinge to the skin’ 
was a sign of chlorosis.(17)  Hart cites the eminent US physician W.Crosby’s 
1955 case of anaemia with green discoloration, which he explained as 
combined protein and iron deficiency.(18) 
Most features of chlorosis fit well with severe IDA in adolescent girls 
and young women. Long before the microscopy of stained blood was 
commonplace, Gabriel Andril had commented on the very small red cells in 
chlorosis.(19) John Coakley Lettsom in 1795, a successful physician who 
founded the London Society of Medicine and the Royal Seabathing Hospital at 
Margate among other institutions, wrote reassuring tracts on a number of 
common medical problem, including one on chlorosis in girl’s boarding 
schools.  
He described the features of chlorosis as paleness and sallowness of 
complexion, palpitations of the heart, difficulty breathing on exertion, bloated 
appearance, loss of appetite, reluctance to exercise and amenorrhoea. 
Amenorrhoea is difficult to explain except that delayed puberty can be a feature 
of severe anaemia, and amenorrhoea features in severe malnutrition.(20) 
One hundred years later, Stockman concluded that excessive menstrual 
loss together with habitually low intake of iron from the diet have the direct 
causes of chlorosis. Treatment was iron.(21) 
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In 1832, Blaud introduced pills containing 1.39g of Ferrous sulphate and 
0.1g of potassium carbonate, and these became widely recommended for 
chlorosis and other conditions.(22) The original pills contained 64mg of iron. 
Many physicians, even into the 1930s, Thomson, Findlay and Osler, thought 
iron was more effective.(23) 
Understanding of IDA by the early 1930s can be summarised by the 
Americans, Wintrobe and Beebe . They stated that ‘there is only presumptive 
evidence that idiopatic hypochromic anaemia develops because an individual is 
unable to meet the demands for haemoglobin or replace the normal loss of 
blood on account of defective utilization of blood building materials in the diet. 
This was the era, when micronutrient deficiencies had been recognized. 
Further, haemorrhagic conditions were known to lead to hypochromic 
microcytic anaemia, so the relevance of balancing iron intakes with needs 
might have been made.(24) 
Defining The Role of Iron in Iron Deficiency Anaemia 
Helen Mackay And The Children Of East London 
After working in Vienna post-World War 1, Helen Mackay, the first 
woman to receive the fellowship of the Royal College of Physicians of London, 
studied young children in East London in the 1920s to determine ‘normal’ 
haemoglobin values for different stages of infancy.(25)  
In earlier studies, Mackay had found that infants attending her clinics 
gained weight when treated for infection and given supplementary milk. These 
interventions had not prevented the decline in haemoglobin levels. 
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Supplementation with iron salts, however, produced dramatic changes. The late 
anaemia of infancy (that is after the physiological post-natal fall) was either 
prevented or, when iron was started after 6 months, diminished in iron-
supplemented infants compared with those not receiving supplementary iron 
Mackay also remarked that iron-treated infants looked much healthier. Iron 
supplemented infants had only around 50% of the episodes of respiratory tract 
infection, diarrhoea and specific fevers experienced by the unsupplemented 
infants.(25) 
Mackay  showed high haemoglobin levels at birth, a gradual fall from 
birth to around 2 months and then (in Mackay’s infants), a steady level until 
further fall from 6 months into the second year. Although the low haemoglobin 
of late infancy seemed more common and more severe in non-breast-fed than 
in breast-fed infants, both methods of feeding led to falling haemoglobin levels, 
hypochromia and microcytosis from 6 months onwards with the most marked 
falls in low-birthweight infants. As it was not known whether these findings 
reflected normal physiology or not, trials of likely therapeutic interventions 
seemed the logical way to resolve the question.(26) 
 Mackay’s studies established the pattern of haemoglobin change in early 
infancy and demonstrated the nutritional vulnerability of premature infants. She 
drew very definite conclusions that the anaemia of late infancy resulted from 
insufficient iron in the diet and could be eliminated by iron therapy. Her 
recommendation, that iron should be given to non-breast-fed infants from the 
first months of life because this can support higher levels of haemoglobin later 
in infancy, stands good today.(25,26,) 
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Iron Deficiency  Anaemia   In  Pregnancy 
Anaemia is the commonest medical disorder in pregnancy.(27) Anaemia 
is a common denominator in most of the maternal death.(28)  
Physiological Change During Pregnancy 
Plasma volume expands in pregnancy. There is a relatively greater 
expansion of plasma volume compared with the increase in  haemoglobin mass 
and red cell volume.(4) 
Iron Requirement In Pregnancy 
The total iron requirement during pregnancy ranges between  
580-1340 mg. Table - 2 shows the iron requirement during pregnancy. 
TABLE - 2 : IRON REQUIREMENTS DURING PREGNANCY(29)  
Sl.no Parameters Average Range 
1 External iron loss 170 mg 150 – 200 mg 
2 Expansion of red cell mass 450 mg 200 – 600 mg 
3 Foetal iron 270 mg 200 – 370 mg 
4 Iron in placenta and cord 90 mg 30 – 170 mg 
5 Blood loss at delivery 150 mg 90 – 310 mg 
6 Total iron requirement 980 mg 580 – 1340 mg 
 
Hence pregnant and lactating women need 5 -6 mg of iron daily in 
food.(29) The recommended dose may be as high as 240 mg / day in developing 
countries.(30) 
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           In 1989, the World Health Organization (WHO) recommended universal 
supplementation of all pregnant women with 60 mg of Ferrous iron twice daily 
in populations where gestational anaemia is common and once daily in 
population where overall iron nutrition is better.(31) Since 1990, National 
nutritional anaemia control programme has been implemented in which the 
dose of iron supplement of women was increased from 60 mg to 100 mg with 
0.5 mg of folate.(32)  
Causes  of  IDA  in  pregnancy 
Dietary  habits : Vegetarians are at an additional  disadvantage because certain 
food stuff that include phytates and phosphates reduce iron absorption by about 
50%.  When ionisable iron salts are given together with food, the amount of 
iron absorbed is reduced.  Iron in vegetable is only about one – twentieth as  
available, egg iron one-eight, liver iron one half and haem iron  one half to two 
third.  Hence  liver  and  haem iron are absorbed nearly as well as iron salt 
added to food, while the iron in vegetables and eggs is much less available.(33) 
Worm Infestation : Iron deficiency anaemia may also arise from certain 
associated illness such as ankylostomiasis.(34) 
Repeated Pregnancy :  Singh et al., reported anaemia to be higher in 
multigravida.(39) 
Maternal Effects :  Anaemia  is associated with palpitation, tachycardia, 
breathlessness  and increased cardiac out put which can lead to  cardiac failure. 
Increased risk of preterm labour is associated with anaemia. Postpartum 
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problems may get aggravated by anaemia, especially failure of lactation, 
puerperal sepsis, subinvolution  of the uterus and delayed wound healing.(4) 
Foetal Effects :  Mola et al., showed maximum still birth rate in severe and 
moderate anaemic group. Increased perinatal mortality rate, preterm birth, 
intrauterine death, low birth weight, early neonatal complications were 
significantly  higher in women with severe  anaemia.(36) 
Symptoms 
Pregnant women with mild anaemia are usually diagnosed by 
performing haemoglobin estimation at the initial visit. Moderate anaemia may 
present with fatigue, dizziness. Breathlessness and palpitation are features of 
severe anaemia.(7) 
Signs 
 Pallor of the tongue and conjunctiva are important signs of anaemia; 
Bilateral pedal edema is common feature of severe anaemia.(7) 
Laboratory   Findings  
Iron deficiency develops in stages. The first stage is  depletion of iron 
stores. At this point there is anaemia but no change in red blood cell size.  
A ferritin value less than 30 micro grams/dl is an indicator of iron deficiency. 
The serum total iron binding capacity rises.  
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After  iron stores have been depleted red blood cell formation will 
continue with deficient supplies of iron. Serum iron values decline to less than 
30 Fg/dl and transferrin saturation to less than 15%. 
In the early stages, mean corpuscular volume remains normal; 
subsequently mean corpuscular volume falls and the blood  smear  shows  
hypochromic  microcytic  cells.  With further progression  anisocytosis and  
poikilocytosis develop. Severe iron deficiency will produce a bizarre peripheral   
smear,  with severly hypochromic  cells,  and  occasionally  small  number  of  
nucleated  red blood cells.(37) 
Treatment 
Iron therapy is indicted only for the prevention or cure of iron 
deficiency. When oral therapy is used there is an enormous variety of official 
and proprietary iron preparations.(38) 
When IDA is diagnosed, the usual treatment is  an oral  iron preparation; 
Several iron  preparations are  available  for oral  administration.(38) 
Oral Iron Therapy 
Sources of Iron  
Diet  
On average, 1000 calories worth of food provides about 6 mg of iron.(39) Meat is 
an important source of haem iron, which is the most bioavailable form of iron 
in the diet. The content of iron in food has been significantly reduced since the 
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stone age, when the diet contained about 28.5 mg of iron per 1000 K.calories, 
compared to presently 4.5 to 5.0 mg per 1000 K.calories.(40) Haem iron is 
highly available for absorption, about 20 – 30% is absorbable. Non-haem iron 
is absorbed less than 5%. Availability is determined by the balance between 
inhibitors – phytates, tannates, phosphates and enhancers – amino acids and 
ascorbic acid.(41) The bioavailability of iron in vegetarian diet is of special 
concern because vegetarians eliminate meat and their diet commonly contain 
more inhibitors of iron absorption such as phytic acid. The absorption of non-
haem iron from a vegetarian diet is up to 70% lower than from non-vegetarian 
diet, which explains why vegetarians often have small iron stores.(42) Tea is a 
stronger inhibitor than coffee, while orange juice and other Vitamin C 
containing food stimulate the uptake of iron.(43) 
Vegetable Foods Rich in Iron  
Green vegetables, peas, beans, bananas, spinach are rich in iron.(39) 
Animal Foods Rich in Iron  
 Meat, liver, heart, crab muscle, fish. Food cooked in iron and stainless 
steel pans can be significant source of iron.(39) 
Iron Preparations 
Ferrous Sulphate 
 Ferrous sulphate is the hydratred salt FeSO4.7H2O, contains 20% of 
iron; it consists of pale bluish green crystal or granules, soluble in 1 : 1.5 in 
water. It effervesces in dry air; in moist air, crystals of ferrous sulphate readily 
  
18
oxidized and become coated with a brownish yellow, basic ferric sulphate and 
must then not be used for medicinal purposes. The drug is odourless  and has a 
saline, astringent taste. It is usually dispensed as pills or tablets coated to 
protect them from moisture. The salt is mixed with glucose or lactose to protect 
it against oxidation. Official ferrous sulphate tablet usually contains 300 mg of 
the salt.(15) 
 
Pharmacokinetics and Pharmacodynamics of Iron  
 
 Iron is quantitatively the most important biocatalytic element in human 
enzymology, with important roles in oxygen transport and storage, oxidative 
metabolism in cellular growth and proliferation. This is because of its ability to 
reversibly and readily cycle between the ferrous(Fe2+) and ferric iron(Fe3+) 
oxidation state. 
 Iron is present in the body in three compartments 
1. Functional iron 
2. Transport iron 
3. Storage iron.(41) 
Functional Iron Proteins  
Haem contains a porphyrin molecule namely protoporphyrin IX, with 
iron at its center. Haemoglobin is a conjugated protein, containing globin – the 
apoprotein part – and the heme – the non-protein part.(44) Four of them in turn 
bind loosely to form the whole haemoglobin molecule.(45) 
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 The functional iron compartment includes iron 30mg/kg as haemoglobin 
iron contained within the circulating red cells and an  additional 6-7mg/kg that 
is present in tissues throughout the body in myoglobin and in a variety of haem 
enzymes and non haem enzymes.(41) 
Transport Iron and Storage Iron 
Apotransferrin is a single chain glycoprotein. Composed of two lobes. 
Each lobe bind a single ferric ion so that the molecule exist as transferrin.  The 
total amount of apotransferrin in human is about 240mg/kg, equally divided 
between the plasma and extravascular fluids. Apotransferrin is produced by 
hepatocytes.(41) 
Transferrin Receptor 
Transferrin receptor is transmembrane glycoprotein. The transferrin 
receptor can bind two molecules of transferrin. They are expressed  virtually on 
all nucleated cells. They are expressed virtually on large numbers in erythroid 
precursors, placenta and liver. The number of transferrin receptor on the cell 
surface is a prime determinant of cellular iron supply. The half life for 
disappearance of transferrin receptors from the cell has been reported to range 
from < 24 hours to 2 – 3days.(41) 
Storage Iron  
Apoferritin is a spherical protein; has two subunits; provide route for 
movement of iron in and out of the interior of sphere. (41) 
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Ferritin is major storage protein. Composed of 24 subunits. Each ferritin 
molecule can reversibly store as many 4500  iron atom with in the cell. 
Catabolism of cellular ferritin may result in digestion of protein shell with 
reutilization of the iron core. Normally, the amount of plasma ferritin 
synthesized and secreted seems to be proportional to the amount of cellular 
ferritin produced in the internal iron storage pathway so that the plasma ferritin 
concentration is related to the magnitude of body iron stores.(41) 
Iron Regulatory Proteins (IRP)  
 IRP–1 and IRP–2. These are proteins involved with regulation of 
cellular iron metabolism called iron regulatory proteins. The two IRPs bind 
with equally high affinity to (IRE)  Iron responsive element.(41) 
 Nramp–2 (National resistance associated macrophage protein) is a 
mammalian iron transporter involved in the transport of iron from the intestinal 
lumen into the enterocytes; controls transport of iron across the endosomal 
membrane for cellular utilization.(41) 
Iron Metabolism At Cellular Level  
Iron Absorption  
 
 Iron is absorbed at the brush border of epithelial cells of the intestinal 
villi particularly in the duodenum and upper jejunum. 
 Gastric juice stabilizes dietary ferric iron; preventing its precipitation as 
insoluble ferric hydroxide. At pH less than 3, ferric iron is stable and binds 
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loosely to mucin. Within the brush border of the epithelial cell a 
transmembrane ferric reductase converts Ferric to Ferrous ion.(46) Nramp-2 
transports iron from the intestinal lumen into the enterocyte.(41) 
 Enhanced level of absorption is found in the iron deficient state, 
increased erythropoietic activity and hypoxia. Second transporter governs the 
movement of mucosal cell iron across the basolateral membrane to bind to 
plasma protein.(29) 
Mucosal Regulation of Iron Absorption  
It is regulated by 
1. Mucosal uptake of iron across the brush border membrane. 
2. Retention of iron in storage form within the mucosal cell. 
3. Transfer of iron from the mucosal cell to the plasma. 
 It is taken up by apotransferrin in the interstitium. It circulates in the 
plasma as transferrin bound iron. Two molecules of transferrin bind to the 
transferrin receptor. This complex is internalized to form a clathrin coated pit. 
In acidic environment iron is released from transferrin and is made available 
for cellular use or storage. When the iron is incorporated into protoporphyrin in 
the mitochondria, haem is synthesized. Any excess iron is stored in the 
cytoplasm as ferritin. Each  transferrin  molecule undergoes  100–200 cycles of 
iron binding and release during its life time in the circulation.(41) 
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Role of Iron Regulatory Proteins  
 Iron regulatory proteins IRR-I and IRP-2 function as both sensors and 
controller of intracellular iron supply.(41)  
 A decrease in intracellular available iron results in an increase in the 
proportion of high affinity IRPS. Increased IRP binding to IRE increases 
transferin receptor protein production but decrease ferritin protein production. 
 An increase in intracellular iron results in fewer IRP binding with IRES, 
decreasing transferin receptor protein production while increasing ferritin 
protein production.(41) 
In the red cells, most iron is utilized for  haemoglobin synthesis. 
Synthesis of haem is linked to iron availability by regulation of  δ amino 
levulinic acid synthetase, which is the first enzyme in the biosynthesis of 
protoporphyrin. The final step in haem synthesis is the formation of heme from 
protoporphyrin IX and ferrous iron catalysed by the mitochondrial enzyme 
ferrochelatase.(41) 
Transport of Iron between compartments 
The catabolism of senescent erythrocyte release iron, which requires 
return to plasma transferrin, for delivery to the erythroid marrow. The 
outpouring of iron to plasma apotransferrin from macrophages in the bone 
marrow, liver and spleen constitute the largest single flux of iron from cells in 
the body. With iron deficiency, all the iron derived from the hemoglobin 
catabolism is promptly returned to the plasma and none is diverted to 
macrophage store. Maximal rate of release from this source in the adult is 
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limited to 40 – 60 mg of iron per day. All the haemoglobin is catabolised, with 
the globin proteolytically processed to aminoacids, releasing heme. The heme 
is transported to the endoplasmic reticulum of the macrophage to be degraded 
by heme oxgenase. Heme oxygenase is a microsomal enzyme that catalyse 
oxidative catabolism of haem to yield biliverdin and iron.(41) 
Iron Excretion 
 Physiologically, iron is excreted by the following mechanism.  
1. Exfoliated epithelial cells of Gastro intestinal tract 
2. Exfoliated cells of skin 
3. Bile 
4. Urine 
5. Sweat 
6. Menstrual blood loss.(46) 
Side Effect of Oral Iron preparations of Iron 
Conventional doses of iron salts used in anaemia may cause 
gastrointestinal reactions such as heart burn, nausea, upper gastric discomfort, 
constipation and diarrhoea. Intolerance to oral iron preparations of iron is 
primarily a function of the amount of soluble iron in the upper gastrointestinal 
tract. Nausea and upper abdominal pain are common. If liquid is given, 
transient staining of teeth also occurs.(29) 
Toxicity of Oral Preparation of Iron  
 Long continued administration of iron results in haemochromatosis. (29)  
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Overdose of Iron  
Accidental iron poisoning occur in children due to ingestion of iron 
preparation intended for adult use. Fatal dose is 2–10 grams. All iron 
preparations should therefore be kept in child proof bottles. 
The earliest manifestations are vomiting, often associated with 
hematemesis, pallor, cyanosis, lassitude, drowsiness, hyperventilation due to 
acidosis and cardiovascular collapse. Death occurs within 12-24 hours. 
Depending upon the concentration of iron in the plasma, treatment is 
offered. If it is less than 3.5 mg/litre, the child is not in immediate danger. If it 
is more than 3.5mg/litre DEFEROXAMINE should be administered. 
 The initial treatment is prompt evacuation of stomach either by inducing 
emesis or gastric lavage. Gastric lavage should be done with sodium 
bicarbonate solution and at the end of lavage, 5 – 10 mg of Deferoxamine 
solution in approximately 60ml of sodium bicarbonate should be left in the 
stomach. Increased serum level require intramuscular administration of 
deferoxamine in doses 0.5 to 1.0 gm. The children who survive initial 3-4 days 
usually recover without much sequalae. Gastric stricture, fibrosis and intestinal 
stenosis are rare late effects.(29) 
Other Iron Preparations  
 Therapy with oral Iron 
 
 Therapy with parenteral iron 
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Therapy with Oral Iron 
 
  
 Iron is absorbed in the ferrous form. Ferrous salts are absorbed about 
three times as well as ferric salts. Various iron preparations are available. 
Ferrous sulphate, Ferrous fumarate, ferrous gluconate, polysaccharide iron 
complex are some of the iron preparations. 
 Other iron compounds have utility in fortification of food. Reduced iron 
(metallic iron, elemental iron) is as effective as ferrous fumarate, provided that 
the material employed has a small particle size.(15) 
Ferrous Fumarate  
 This salt occurs as an anhydrous, reddish brown granular powder. It 
contains 33% of iron and is moderately soluble in water, stable and almost 
tasteless. Unlike ferrous sulphate it does not require mixing or coating with 
glucose to protect it against oxidation. Official ferrous fumarate tablets usually 
contain 200 mg of the salt. The average adult dose is 3 – 4 tablets daily.(15) 
Ferrous gluconate  
 Gluconate contains 12% of metallic iron. (15) 
Ferrous lactate  
Ferrous lactate contains 9% of metallic iron.(15) 
The average dose for the treatment of iron deficiency anaemia is about 
200 mg of iron per day (2–3 mg/kg), given in three equal dose of 65 mg. When 
the object is the prevention of iron deficiency in  pregnant  women  a dose  of 
15–30 mg of iron per day is adequate to meet the 3–6 mg daily requirement of 
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the last two trimesters. When the purpose is to treat iron deficiency anaemia, a 
total dose of about 100 mg may be used(15). 
Therapy with parentenal iron 
 When oral therapy fails, parenteral iron administration may be an 
effective alternative. Indications are severe oral iron intolerance and in patients, 
with renal disease who are receiving erythopoietin. Parenteral iron therapy 
should be used only when clearly indicated, since acute hypersensitivity, 
including anaphylactic and anaphylactoid reactions can occur in from 0.2% to 
3% of patients. 
 Iron dextran injection is the parenteral preparation. It contains 50mg/ml 
of elemental iron. It can be administered Intramuscularly or Intravenously. 
Sodium ferric gluconate complex in sucrose : Another parenteral iron 
preparation used in patients undergoing chronic haemodialysis who are 
receiving supplemental erythropoietin therapy. 
Reactions to parenteral therapy include arthralgia, fever and rare 
anaphylactic reaction, which may be fatal inspite of treatment. Thus, there must 
be specific indications for the parenteral administrations of iron(29). 
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CARBONYL IRON 
Chemistry 
 Carbonyl iron powder is an elemental iron preparation.(47) As per Sacks 
PV and Houchin DN, carbonyl iron powder does not refer to the composition 
of the iron particles but refer to the manufacturing process in which controlled 
heating of vapourised iron pentacarbonyl leads the deposition of uncharged 
elemental iron as submicroscopic crystals, that form microscopic spheres of 
less than 5µm in diameter.(48) As per HL Sharma and KK Sharma, the time 
required for disintegration is saved in powders. This is the rate limiting step in 
the process of absorption and bioavailability.(49) 
 
FIGURE - 4   :  CARBONYL IRON 
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Bioavailability 
Size and Shape 
 The Carbonyl iron powder is microscopic spheres of less than 5µm in 
diameter.(48) A drug usually dissolves more rapidly when its surface area is 
increased by decreasing its particle size. This facilitates their absorption and 
hence enhances the bioavailability.(49) 
Elemental Iron Content 
 The preparation is 98% pure.(48) Absorption also depends upon the iron 
content. Amount of iron rather than in the mass of the total salt in iron tablet is 
important.(29) 
 In a randomized double blind study for bioavailability of carbonyl iron 
by Devasthali et al, after 16 weeks of therapy, the mean increase in hemoglobin 
iron was similar in both groups. Estimate of net changes in total body iron 
suggested that the overall bioavailability of carbonyl iron was high about 70% 
that of  ferrous sulphate.(50) 
Pharmacokinetics  
Absorption  
 The conversion of particulate carbonyl iron to soluble ionized iron by 
stomach acid was a prerequisite for absorption and was limited by the rate of 
gastric acid production. With carbonyl iron, only that fraction solubilized by 
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gastric acid is available for absorption; in addition, the rate of solubilisation is 
restricted by the rate of gastric acid production.(51) 
 In a randomized double blind trial by Victor R.Gordeuk et al., in high 
dose carbonyl iron for iron deficiency anaemia, comparing high dose of 
carbonyl iron (1800mg/day) and a standard ferrous sulphate therapy 
(180mg/day) for the short term (3 week) treatment of mild iron deficiency 
anaemia. There was no significant difference in overall incidence of 
gastrointestinal side effects observed with the two forms of iron although the 
dose of iron as carbonyl iron was 10 times that of ferrous sulphate. In these 
studies, the conversion of particulate carbonyl iron to soluble iron by stomach 
acid was prerequisite for absorption and was limited by rate of gastric acid 
production.(51) 
Sustained Absorption 
 With carbonyl iron, serum iron increase was less abrupt but more 
sustained, with maximal increase occurring at the end of six hour period of 
observation.(52) 
Side Effects 
Gastrointestinal side effects such as diarrhoea and unpleasant taste was 
noted only with 3000 mg carbonyl iron as single dose.(52) 
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Toxicity 
 Crosby suggested that carbonyl iron may be an ideal therapeutic agent, 
effective, yet lacking in toxicity.(53) 
Human volunteers have taken oral dose of 10,000mg of carbonyl iron. 
About 140 mg Fe/kg without deleterious effect.(53) Toxicity studies of carbonyl 
iron in rats and guinea pigs found that the LD0 was 10,000 to 15,000 mg 
iron/kg and the lethal dose LD100 was 50,000 to 60,000 mg of iron/kg.(47) 
 Since the lethal dose is high, there is no risk of poisoning in children in 
case of accidental poisoning. In a multicenter retrospective evaluation of 
carbonyl iron ingestion by Spiller et al, retrospective chart review of all 
patients were collected. Thirty three patients with carbonyl iron ingestion were 
reported. Twenty seven patients were managed without referral to a health care 
facility. The mean and median age of these patients was 3 years and 20 months 
respectively. The mean dose ingested was 11.2 mg/kg (range of 2.2 to 
34.5mg/kg) with no effects noted. Six patients evaluated in the emergency 
ingested a mean of 34 mg/kg (range of 12 to 72 mg/kg). The mean peak serum 
iron concentration  in 4 out of 6 were 82µg/dl (range of 36 to 177 µ/dl). One 
child with a history of flu like symptoms reported diarrhoea, fever and lethargy 
and had a serum iron concentration of 36 µg/dl; in this study, serious toxicity 
did not occur.(54) 
 In another study of acute toxicity of carbonyl iron and sodium iron 
EDTA compared with ferrous sulphate in young rats by Whittakar.P, Ali.SF, 
Iman SZ, Dunkal VC, both sodium iron EDTA and carbonyl iron were 
compared with Ferrous sulphate, to obtain information relevant to the acute 
toxicological profile in young rats. With FeSO4 and sodium iron Ethylene 
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diamine tetra-acetate (NaFeEDTA), total liver non haem iron increased with 
increasing dose, but the response was approximately 50% lower with 
NaFeEDTA compared with ferrous sulphate. Serum iron peaked at 
approximately 0.5 to 1 hour for both ferrous sulphate and carbonyl iron, while 
NaFeEDTA was elevated upto 4 hours. Ferrous sulphate has an LD50 of 1.1 g 
Fe/kg and was approximately 45 times more toxic than carbonyl iron, which 
had an LD50  greater than 50 g Fe/kg. NaFeEDTA had an LD50 of 1.3 g Fe/kg 
and when compared with ferrous sulphate had approximately the same level of 
toxicity.(55) 
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AIM OF STUDY 
Study objectives 
Primary objective 
 To compare the efficacy of carbonyl iron formulations with  
ferrous  sulphate  in  pregnant women with  iron  deficiency  anaemia. 
Secondary objective 
 To assess the tolerability of carbonyl iron. 
 To record the adverse effects of carbonyl iron. 
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METHODOLOGY 
STUDY CENTER  : ANTENATAL OUTPATIENTS  
DEPARTMENT OF INSTITUTE OF  
     OBSTETRICS AND GYNAECOLOGY, 
     MADRAS MEDICAL COLLEGE 
 
STUDY PERIOD   : DECEMBER 2.12.2004 TO 22.12.2005 
 
STUDY DESIGN  : OPEN LABELLED  
SYSTEMATIC RANDOM SAMPLING  
PARALLEL GROUP COMPARATIVE,  
PROSPECTIVE STUDY 
 
STUDY DURATION : 12 WEEKS 
 
INCLUSION CRITERIA : AGE- 20-40 YEARS 
Hb LEVEL7-9gm % 
PREGNANCY > 16 TO <20 WEEKS OF 
GESTATION 
 
EXCLUSION CRITERIA : Hb LEVEL  : LESS THAN 7gm% 
   PREGNANCY WITH LESS THAN 16 
WEEKS OF GESTATION 
   OTHER : HYPER EMESIS 
   PREGNANCY INDUCED HYPERTENSION  
   ANAEMIA WITH   CARDIAC  FAILURE 
   OTHER SYSTEMIC DISEASES 
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STUDY PROCEDURE 
The study was conducted after obtaining clearance from Institutional 
Ethical Committee.  Pregnant women attending the antenatal out patients 
department of Institute of Obstetrics and Gynaecology, Madras Medical 
College were explained about the purpose and procedure of the study. 
The demographic data was recorded and screened for anaemia by 
history, clinical examination and haemoglobin estimation. Among them 60 
pregnant women, who fulfilled the inclusion criteria were enrolled for the 
study. Written informed consent was obtained from those, who were willing to 
participate in the study. The demographic baseline laboratory investigations - 
RBC count, packed cell volume, haemoglobin estimation, blood urea, serum 
creatinine, SGOT, SGPT, Bilirubin, urine routine analysis, motion for ova, cyst 
and occult blood were estimated. The 60 pregnant women were enrolled by 
systematic random sampling  into one of the three treatment groups. Every  
1st patient enter Group I and the second patient in Group II and 3rd patient to 
Group III. The same was followed till each group had 20 patients. 
Treatment Group 
Group I - Received - 10 ml of syrup corbonyl containing 50 mg of 
carbonyl iron twice daily (elemental iron 98 mg) for 12 weeks. 
Group II - Received - 1 capsule of carbonyl iron 100 mg, (elemental iron 
98 mg) once daily for 12 weeks. 
Group III - Received - 1 tablet of Ferrous sulphate 200 mg (elemental 
iron 40 mg) once daily for 12 weeks. 
Follow up was given at the end of every 4 weeks apart from the regular 
antenatal checkup. They were asked to return the empty packs/bottles and were 
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issued respective drugs for the subsequent 4 weeks. They were also asked to 
report regarding the adverse effects and the same was recorded.  
The laboratory investigations  
• Haemoglobin estimation 
• RBC count 
• Packed cell volume 
were estimated at the baseline, at the end of 4th, 8th and 12th week of the 
study.  
Blood Chemistry  
 Blood urea, sugar,  serum creatinine, (SGOT) serum glutamic oxaloacetic 
transaminase, (SGPT) serum glutamic pyruvic transminase and bilirubin level 
were estimated at baseline and at the end of 12th week.  
Urine analysis was done at the baseline and at the end of 4th, 8th and 
12th week. 
 Motion examination for ova, cyst and occult blood was done at the 
baseline. 
Followup 
 The patients were followed up till delivery even after completion  of the 
study. Those who could not tolerate the drugs were allowed to withdraw from 
the study. At the end of the study, the data were compiled and analysed 
statistically by ANOVA-F test and ANOVA-T test. 
Primary End Point 
 To achieve a haemoglobin level of 12g/dl or more than 11 g/dl 
Secondary End Point 
 To study the tolerability and drug related adverse effects.  
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Statistical Analysis 
  Demographic profiles were given in frequencies with their percentages 
for each group.   
 Age, Height, Weight difference between groups were analysed by using 
one way analyses of variance (ANOVA) F-test. 
 Blood chemistry and haemogram between groups were analysed by 
using ANOVA  t-test. 
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RESULTS 
Among the 114 pregnant women  screened, 60 pregnant women who 
fulfilled the inclusion criteria were enrolled for the study. 57 completed study. 
There were 3 drops outs. The 3 drops were from ferrous sulphate group.  
Total Pregnant women Screened for the study : 114 
Pregnant women enrolled      :  60 
Pregnant women completed the study    :  57 
Drop outs ( from Tablet. Ferrous sulphate group)  :  03 
Reason 
1. Lost for follow up     :  01 
2. Withdrawl from the study    :  02 
   (Heart burn 1, diarrhoea - 1) 
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DEMOGRAPHIC CHARACTERISTICS 
TABLE – 4  :  MEAN AGE 
Sl.No. Group Mean 
1. Syrup-Carbonyl 25.05 
2. Capsule -Carbonyl 24.15 
3. Tab. Ferrous sulphate 24.12 
                      (p value = 0.68) 
Table – 4 shows the mean age of the three study groups  
Mean age in syrup carbonyl iron group :   25.05 (years) 
Mean age in capsule  carbonyl iron group:  24.15 (years) 
Mean age in Tablet ferrous sulphate :   24.12 (years) 
 
TABLE – 5  :  MEAN HEIGHT 
Sl.No. Group Mean 
1. Syrup-Carbonyl 148.00 
2. Capsule -Carbonyl 151.85 
3. Tab. Ferrous sulphate 148.12 
                     (p value = 0.29) 
The table- 5 describes the mean height of pregnant women in the three 
study groups.  
Mean height in syrup carbonyl iron group  :  148 cms 
Mean height in capsule  carbonyl iron group :  151.85 cms 
Mean height in tablet ferrous sulphate group :  148.12 cms. 
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TABLE – 6   :  MEAN WEIGHT (kgs) 
Sl.No. Group Mean 
1. Syrup-Carbonyl 45.00 
2. Capsule -Carbonyl 44.75 
3. Tab. Ferrous sulphate 45.00 
          (p value = 0.99) 
Table – 6  shows the mean weight in the three study groups.  
Both syrup carbonyl iron and Tablet ferrous sulphate shows the mean 
weight of 45.0 kg. whereas capsule  carbonyl iron had 44.75 kg. as  mean 
weight. 
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TABLE – 7  : MEAN BLOOD PRESSURE (mm of HG) 
Sl.No. Group Mean 
 Systolic blood pressure  
1. Syrup-Carbonyl 111.90 
2. Capsule -Carbonyl 109.00 
3. Tab. Ferrous sulphate 120.00 
                                       (p value =0.35) 
 
 Diastolic blood pressure  
1. Syrup-Carbonyl 80.40 
2. Capsule -Carbonyl 79.00 
3. Tab. Ferrous sulphate 81.53 
                                               (p value  0.28) 
Table 7  shows the mean systolic and diastolic  blood pressure in the 
three groups. 
The mean systolic BP was 111.90 in syrup carbonyl iron group 
The mean systolic BP was 109.00  in capsule-carbonyl iron group 
The mean systolic BP was 120.00 in Tab. ferrous sulphate iron group 
 
The mean diastolic BP was 80.40 in syrup carbonyl iron group 
The mean diastolic BP was 79.00  in capsule-carbonyl iron group 
The mean diastolic BP was 81.53  in Tab. ferrous sulphate iron group 
Systolic blood pressure (p value = 0.35) 
Diastolic blood pressure (p value = 0.28) 
  
41
TABLE - 8 :  MEAN HAEMOGLOBIN LEVEL 
Group 
Weeks 
Syrup-carbonyl Capsule-Carbonyl Tab-Ferrous Sulphate 
0 8.40 8.57 8.35 
4 10.57 11.05 9.45 
8 11.43 11.73 9.97 
12 11.96 12.09 10.41 
               (p value - 0.001) 
 
The above table 8, shows the mean Hb gm % of all the 3 group  
at baseline (0), at the end of 4th, 8th and 12th week respectively. 
The mean Hb%  for syrup-carbonyl iron at the baseline     8.40  gm % 
The mean Hb%  for syrup-carbonyl iron at the end of 12th week    11.96 gm % 
 
The mean Hb%  for capsule-carbonyl iron at the baseline      8.57 gm % 
The mean Hb%  for capsule-carbonyl iron at the end of 12th week     12.09 gm % 
 
The mean Hb%  for tab-ferrous sulphate iron at the end of baseline  8.35gm % 
The mean Hb%  for tab-ferrous sulphate iron at the end of 12th week   10.41gm % 
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TABLE - 9  :  MEAN RED BLOOD  CELL COUNT 
Group 
Weeks 
Syrup-carbonyl Capsule-Carbonyl Tab-Ferrous Sulphate 
0 3.27 3.41 3.17 
4 3.58 3.77 3.31 
8 3.76 3.92 3.42 
12 3.89 4.04 3.51 
             (p value - 0.001) 
 
Table-9 furnishes the mean RBC count among the three groups at 
baseline, at the end of 4th , 8th and 12th week of the study.  
The mean RBC count for syrup-carbonyl iron at the baseline                3.27 
The mean RBC count for syrup-carbonyl iron at the end of 12th week           3.89 
 
The mean RBC count  for capsule-carbonyl iron at the baseline                 3.41 
The mean RBC count for capsule-carbonyl iron at the end of 12th week          4.04 
 
The mean RBC count for tab-ferrous sulphate iron at the end of baseline         3.17 
The mean RBC count for tab-ferrous sulphate iron at the end of 12th week      3.51 
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TABLE-10  :  MEAN PACKED CELL VOLUME 
Group 
Weeks 
Syrup-carbonyl Capsule-Carbonyl Tab-Ferrous Sulphate 
0 27.90 28.80 26.88 
4 32.90 33.75 28.78 
8 34.20 35.70 29.71 
12 35.25 37.15 30.53 
               (p value =0.001) 
Table-10 shows the mean packed cell volume for syrup carbonyl iron, 
Capsule  Carbonyl iron and Tablet Ferrous sulphate at the baseline, at the end 
of 4th, 8th and 12th week of the study. 
The mean packed cell volume for syrup-carbonyl iron at the baseline         27.90 
The mean packed cell volume for syrup-carbonyl iron at the end of 12th week           35.25 
 
The mean packed cell volume for capsule-carbonyl iron at the baseline         28.80 
The mean packed cell volume for capsule-carbonyl iron at the end of 12th week          37.15 
 
The mean packed cell volume for tab-ferrous sulphate iron at the end of baseline          26.88 
The mean packed cell volume for tab-ferrous sulphate iron at the end of 12th week      30.53 
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TABLE -11  :  SIDE EFFECT PROFILE 
GROUP 
SIDE EFFECT 
Syrup 
Carbonyl iron 
Capsule  
Carbonyl iron 
Tablet Ferrous 
sulphate 
CONSTIPATION NIL NIL 5 (29.4%) 
DIARRHOEA NIL NIL 12 (70.6%) 
HEART BURN NIL NIL 12 (70.6%) 
EPIGASTRIC PAIN NIL NIL 15 (91.4%) 
VOMITING (3) 15% NIL NIL 
 
Table-11, which describes side effect shows that there was no 
constipation, diarrhoea, heartburn and epigastric pain in syrup and capsule 
carbonyl iron groups.  Vomiting was present in (3) 15% of syrup carbonyl iron 
group. In tablet ferrous sulphate group except for vomiting all other side effects 
were reported.  
  
45
DISCUSSION 
Nutritional anaemia is a world wide problem with the highest prevalence 
in developing countries. It is estimated to affect nearly two third of pregnant 
women and one half of non-pregnant women in developing countries.(1)  
Detrimental Effect 
Agarwal reported that maternal anaemia resulted in 12 to 28% of  
foetal loss, 30% of perinatal death and 7-10% of neonatal death. Low birth 
weight is the most important factor in determining the chance of survival of the 
new born.(56) Klenanoff et al., stated that anaemia during the second trimester 
was associated with preterm birth. Preterm delivery increased five fold in iron 
deficiency anaemia.(57) Anaemia in pregnancy is also associated with increased 
maternal mortality. Maternal death to the extent of 15-20% are directly or 
indirectly due to anaemia.(58) 
 Anaemia which is a common denominator of maternal and foetal 
morbidity and mortality, can be treated effectively by oral iron therapy. Hence 
this study was chosen having carbonyl iron as the oral iron and compared with, 
Ferrous sulphate to assess the efficacy and tolerability in IDA during 
pregnancy. 
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 This prospective, comparative, systematic random sampled open 
labelled study was carried out in the pregnant women attending the out patient 
department at Institute of Obstetrics and Gynaecology, Madras Medical 
College.  
114 of them were screened and 60 of them who fulfilled the inclusion 
criteria were enrolled for the study. By systematic random sampling technique, 
they were assigned to receive either syrup carbonyl iron 50mg twice daily, 
capsule  carbonyl iron 100mg once daily, or tablet ferrous sulphate 200mg once 
daily for 12 weeks. Among the 60, 57 of them had successfully completed the 
study. Three of them belonging to ferrous sulphate group were the drop outs. 
One did not come for follow up; two others with drew because one complained 
of diarrhoea and the other had heart burn. 
The three groups were comparable in terms of age, height and weight at 
the base line and was not found to be statistically significant indicating that the 
study was conducted among the groups having similar baseline characters.  
p value for age   = 0.68 
p value for height   =  0.29  
p value for weight   =  0.99  
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Erythropoietic Efficacy 
 This study has succeeded in demonstrating the efficacy, which was 
realised as increase in Haemoglobin level, RBC count and Packed cell volume 
with minimal gastrointestinal side effects. Effect of therapy on haematological 
parameters is depicted in Table - 8, 9, 10. 
 Haemoglobin level : All the three groups shared an increase in 
haemoglobin level at the end of 4th week and it was greater in carbonyl iron 
groups than ferrous sulphates. At the end of 12 weeks all the three groups had a 
further increase in haemoglobin level and the recommended 12 gm/dl was 
achieved in carbonyl group but was not achieved with ferrous sulphates.  
Statistical analysis by repeated measure analysis of variance shows 
significant difference in capsule carboynl iron (p=0.001). Statistical analysis 
between weeks in all the groups showed a significance difference (p=0.001). 
Other studies corroborate this finding. Gordeuk VR, Brittenham GM, 
Mc Laren.CE, Hughers MA, Keating LJ demonstrated in their study that 
anaemic volunteers who were treated with carbonyl iron daily showed a mean 
daily increase in haemoglobin of 0.01 + 0.01 gm/dl.(52) 
 In another randomised double–blind study, regarding bioavailability of 
carbonyl iron, Devasthali SD, Gorduek VR, Brittenham GM, Bravo JR, 
Hughes MA, Keating LJ demonstrated that 49 female blood donors with iron 
deficiency anaemia were treated with equal doses iron either as carbonyl iron 
or ferrous sulphate in a randomised double-blind fashion. Mean value for 
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haemoglobin concentration, mean corpuscular volume, reticulocyte count did 
not differ significantly between the two groups, through out the study. After  
16 weeks of the therapy , the mean increase in haemoglobin iron was similar 
with both groups. Estimates of  net changes in total body iron suggested that 
overall bioavailability of carbonyl iron was high, about 70% that of ferrous 
sulphate.(50) 
In accordance with the study by Swain JH, Hunt J.R 2002 in their study 
stated that carbonyl iron is a more effective haemoglobin repletion agent with 
more bioavailability than the reduced iron powder forms. (59) 
 In our study also both syrup and capsule  carbonyl iron had statistically 
significant increase in haemoglobin level.  Among the three groups the increase 
was  significantly higher in the capsule carbonyl iron group as compared with 
syrup carbonyl iron and ferrous sulphate group.  
 In the study by Gordeuk et al, 25 healthy volunteers were given orally a 
solution containing 498mg of ferrous sulphate (100mg of elemental iron) and 
100mg of ascarbic acid. Five volunteers received carbonyl iron in single 
incremental doses of 100mg, 1000mg and 5000mg at approximately 1 week 
interval. With 100mg of carbonyl iron  the rise in serum iron was less abrupt, 
but more sustained with maximal increase occurring at the end of 6 hour period 
of observation. These studies revealed that there is an increase in haemoglobin 
level, mean corpuscular volume and serum iron level with carbonyl iron.(52) 
 In our study, the red blood cell count (RBC) also showed a statistically 
significant increase of in syrup carbonyl iron, capsule  carbonyl iron and tablet 
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ferrous sulphate groups respectively. The statistically significant increase was 
greater in the capsule carbonyl iron group compared to that seen in syrup 
carbonyl and ferrous sulphate group. 
In our study capsule carbonyl had a better response (p value =0.001). 
The haemotocrit values also showed a statistically significant increase  
in capsule carbonyl iron, syrup carbonyl iron and tablet ferrous sulphate. The 
increase in haemotocrit value was significantly greater in carbonyl iron both 
within the groups and in between the groups. 
Statistical analysis by repeated measure analysis of variance shows 
significant difference between groups (p=0.001) and weeks wise significance 
difference (p=0.001). 
Analysis of our study results showed that capsule carbonyl iron group 
had registered a statistically significant increase in haematological response 
over syrup carbonyl iron and tablet ferrous sulphate group. 
Blood chemistry 
 SGOT, SGPT bilurubin blood urea and serum creatinine remained 
within the normal range in all the three groups at the basement and at the end of 
the study. Statistical analysis shows no significant change. 
Tolerability 
 Gastrointestinal side effects like constipation, diarrhoea, heart burn, and 
epigastric pain were noticed with tablet ferrous sulphate group. The 
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gastrointestinal side effects were absent with carbonyl iron groups although  
3 patients registered vomiting  in syrup carbonyl iron group. 
Our study results coincides well with study on higher dose carbonyl iron 
for iron deficiency anaemia by Gorduek etal. A randomised double-blind trial 
comparing high doses of carbonyl iron(1800mg/day) and standard ferrous 
sulphate therapy(180mg/day) for short term (3week) treatment of mild iron 
deficiency anaemia. High dose carbonyl iron was well tolerated. These results 
suggest that the principal advantage to the use of carbonyl iron derive from its 
safety.(51) 
According to the study conducted by Reddiah VP et al., to determine the 
optimum dose of supplemental iron for prophylaxis against pregnancy anaemia. 
110 pregnant women randomly allocated to the three groups. Group A 
receiving equivalent of 60mg, Group B 120mg, Group C 240mg of elemental 
iron as Ferrous sulphate daily. The content of folic acid was constant in all the 
three groups. These women had atleast consumed 90 tablets in 100 +/– 10 days. 
Blood was drawn at the beginning and at the end of the study. Fifty percent 
were anaemic (less than 11gm/100ml). The haemoglobin levels rose similarly 
in all groups and the difference were statistically not significant. 56% had 
depleted iron stores, at the beginning of the study. The side effects increased  
with increasing doses of iron; 32.4%, 40.3% and 72% in groups A,B,C 
respectively. Based on these findings the authors advocate the optimum dose 
iron should be 120mg instead of 60mg as is currently being used in the 
National anaemia programme.(60)  Hence the dose of carbonyl iron was chosen 
to be 100 mg once daily. 
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SUMMARY AND CONCLUSION 
 
Sixty antenatal anaemic mothers were grouped into three.  
Group I - Received - 10 ml of syrup carbonyl iron containing 50 mg of 
carbonyl iron twice daily (elemental iron 98 mg) for 12 weeks. 
Group II - Received - 1 capsule of carbonyl iron 100 mg, (elemental iron 
98 mg) once daily for 12 weeks. 
Group III - Received - 1 tablet of Ferrous sulphate 200 mg (elemental 
iron 40 mg) once daily for 12 weeks. 
Basal laboratory investigation were done before and after the treatment. 
Primary end point for the study was to achieve haemoglobin level  more than 
11 gm/dl. Secondary end point was to study the compliance, tolerability and 
adverse drug effects. 
We concluded that there was no significant change in basal laboratory 
and clinical parameters after the study. 
There is significant increase in haemoglobin level, RBC  
count, haemotocrit values in both Group I and II. As far as the side effects 
constipation, heart burn and epigastric pain are nil with Group I and II. 
Vomiting was reported in 15% of syrup carbonyl iron. Gastro intestinal side 
effects were more in tablet ferrous sulphate than the other two groups. 
It is concluded that capsule carbonyl iron is the best preferred therapy in 
efficacy and tolerability than syrup carbonyl iron and tablet ferrous sulphate.  
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IRE  - Iron Responsive Element 
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NaFeEDTA - Sodium iron Ethylene diamine Tetra-acetate 
NFHS-2 - National Family Health Services 
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RBC  - Red Blood Cells 
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SGPT  - Serum glutamic pyruvic transaminase 
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